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Protection from ototoxicity of intraperitoneal gentamicin in Aminoglycoside antibiotics are indispensable for the
guinea pig. treatment of infections, especially those caused by gram-
Background. Aminoglycoside antibiotics are common to negative bacteria, including Pseudomonas aeruginosa,treat peritonitis and exit-site infections in patients on peritoneal
Klebsiella, and Serratia marcescens. They are not signifi-dialysis. Ototoxicity (loss of hearing or balance) is a well-docu-
cantly absorbed after oral dosing, and their most fre-mented adverse effect of aminoglycosides, and severe ototoxic
reactions have been noted in patients receiving these drugs quent application is by intravenous or intramuscular
by intraperitoneal lavage. We have proposed a free-radical routes. In addition, cystic fibrosis patients may receive
hypothesis for the mechanism of aminoglycoside ototoxicity aminoglycosides by inhalation [1, 2], and their intraperi-and suggested a therapeutic prevention by the concomitant
toneal administration is common to treat peritonitis andadministration of antioxidants or iron chelators. Here we inves-
exit-site infections in chronic renal failure patients [3–5].tigate whether 2,3-dihydroxybenzoate can prevent the ototoxi-
city of intraperitoneal gentamicin. The potential for cochlear and vestibular side effects
Methods. Two strains of pigmented guinea pigs received (loss of hearing or balance) is associated with all forms of
daily intraperitoneal injections of gentamicin. Both strains de-
aminoglycoside treatment. For the two rather divergentveloped ototoxicity, although different dosages were needed
routes of systemic injection and inhalation, an incidenceto produce similar auditory deficits (120 mg gentamicin base/kg
body weight daily for 19 days vs. 135 mg/kg for 14 days). of ototoxicity of around 20% has been documented [2, 6].
Dihydroxybenzoate was administered intraperitoneally once Comprehensive data for intraperitoneal application are,
or twice daily. Auditory thresholds were measured by evoked to the best of our knowledge, not available, and some
brain stem response. Pathology was assessed as a loss of sensory
studies suggest a minimal risk of acute ototoxicity [7].cells in surface preparations of the organ of Corti.
However, systemic absorption of aminoglycosides acrossResults. The auditory threshold shifts and hair cell loss were
similar to the pathology observed following subcutaneous in- the peritoneal membrane is rapid and can lead to signifi-
jections of gentamicin. Animals sustained almost complete loss cant serum levels [8–10]. Consequently, both hearing loss
of outer hair cells in the basal cochlea and a progressive hearing and vestibular toxicity have been observed after chronicloss with threshold shifts of 60 dB at 18 kHz. The concomitant
peritoneal dosing of aminoglycosides [11–14] and evenadministration of dihydroxybenzoate significantly attenuated
after a single dose of peritoneal neomycin [15].the threshold shift to less than 30 dB and reduced the loss of
hair cells. The treatment with dihydroxybenzoate did not affect We have recently proposed a novel hypothesis for the
serum gentamicin levels. mechanism of aminoglycoside toxicity and developed a
Conclusions. Antioxidant therapy is a promising approach successful prophylactic treatment in guinea pigs. Amino-to prevent aminoglycoside-induced hearing loss following in-
glycosides can chelate iron, and the resulting iron com-traperitoneal application.
plex is redox active, catalyzing the formation of free
radicals [16–19]. Accordingly, ototoxicity of systemically
injected aminoglycosides could be prevented through
the concomitant administration of antioxidants or iron
chelators. Both hearing loss and vestibular dysfunction
1 Permanent address: Faculty of Pharmaceutical Sciences, Department induced by gentamicin, kanamycin, or streptomycin were
of Pharmacy, Chulalongkorn University, Bangkok 10330, Thailand significantly attenuated without compromising the anti-
bacterial efficacy of the drug [20, 21]. The effectiveness ofKey words: aminoglycosides, hearing loss, antioxidant therapy, exit-
site infection, iron chelators. antioxidant treatment was subsequently confirmed and
extended to neomycin and amikacin [22, 23].Received for publication March 15, 2000
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route is seldom used in experimental aminoglycoside logical saline, pH 7.4; DHB was dissolved by briefly
warming in 5% NaHCO3 at a concentration of 100 mgresearch, and therefore, little is known about pharmaco-
kinetics and the development of ototoxicity in this form DHB/mL. The pH of all solutions was between 4.5 and
7.4. In animals not receiving DHB, saline was substituted.of application. We chose 2,3-dihydroxybenzoate (DHB)
as a potential prophylactic agent because of its previously Body weight of animals was monitored daily, and the
administered dosages were adjusted accordingly. Genta-established protective qualities against aminoglycoside-
induced loss of hearing and vestibular function [20, 21, micin treatment slowed weight gain during treatment.
After the end of treatment, animals resumed a normal24], its beneficial effects on gentamicin-induced nephro-
toxicity [25], and general low toxicity [26]. rate of weight gain.
Serum values
METHODS
Blood was obtained by nail clipping after light anesthe-
Materials sia of the animals with Metofane inhalation. For gentami-
cin pharmacokinetics, two animals each were injected withGentamicin sulfate was purchased from Spectrum
Chemical (Gardena, CA, USA), DHB from Aldrich doses of 60, 100, 120, and 180 mg gentamicin base/kg body
weight. Blood samples were taken at intervals betweenChemical Co. Inc. (Milwaukee, WI, USA), Metofane
from Schering-Plough Animal Health Corp. (Union, NJ, 15 minutes and 3 hours after the gentamicin injections.
Blood cells were removed by centrifugation at 1000 3 gUSA). Ketamine was Ketasett from Fort Dodge Animal
Health (Fort Dodge, IA, USA). Xylazine was Tranqui for 15 minutes, and sera were stored at 2208C. Gentamicin
was measured using a disk diffusion assay. EscherichiaVedt from Vedco Inc. (St. Joseph, MO, USA).
coli (LE392) were suspended in melted 0.7% agar and
Experimental animals and treatment groups poured over a tryptone agar bed. Ten microliter aliquots
of either a standard solution of gentamicin or a serumPigmented male guinea pigs initially weighing 250 to
300 g (Murphy’s Breeding Laboratories, Plainfield, NJ, sample were pipetted onto 1 cm paper disks, which were
placed on the bacterial lawn. The plates were incubatedUSA, or Elm Hill Breeding Laboratory, Chelmsford,
MA, USA) had free access to water and a regular guinea overnight at 378C, and the inhibition zones were mea-
sured.pig diet (Purina 5025; Purina, St. Louis, MO, USA). The
animals were allowed one week of acclimation before For the determination of blood urea nitrogen (BUN),
serum albumin, creatinine, and gentamicin levels in thetreatment was begun. All experimental protocols were
authorized by the University of Michigan Committee on study on twice-daily protection, blood was taken from
six animals per group one hour after the gentamicinUse and Care of Animals. Animal care was under the
supervision of the University of Michigan’s Unit for Lab- injection on day 14. Samples were analyzed by the Clini-
cal Chemistry Laboratory at the University of Michiganoratory Animal Medicine.
The ototoxic effects of intraperitoneal injections of Hospital using a fluorescence polarization immunoassay
for gentamicin (Abbott Laboratories, Abbott Park, IL,gentamicin alone or in combination with DHB were as-
sessed in two strains of guinea pigs, necessitated by a USA) and VITROSt test methodologies (Johnson &
Johnson Clinical Diagnostics, Raritan, NJ, USA) for thechange to a specific pathogen-free strain (Elm Hill) in
the course of the study. Both strains were susceptible to other assays.
aminoglycoside ototoxicity, although different dosages
Evaluation of auditory functionwere needed to produce similar auditory deficits (ab-
stract; Halsey et al, Assoc Res Otolaryngol 23:206, 2000). Auditory thresholds were measured as evoked audi-
tory brainstem response (ABR). Thresholds were deter-Both strains also showed protection by DHB. Guinea
pigs from Murphy’s Breeding Laboratories were used mined for each animal prior to the beginning of the
study, again at day 14, and then weekly up to week 7,for pharmacokinetics and an initial protection study in
which they received 120 mg gentamicin base/kg body as stated in the figure legends.
For ABR recordings, animals were anesthetized withweight daily for 19 days, alone or combined with once-
daily 100 mg DHB plus 15 mg mannitol/kg body weight an intramuscular injection of 60 mg ketamine/kg body
weight and 8 mg xylazine/kg. Measurements were per-[20]. In all other studies, Elm Hill animals were treated
with 135 mg gentamicin base/kg body weight for 14 days, formed in a sound-proof booth at 3, 8, and 18 kHz. In
brief, tone bursts of 3, 8, and 18 kHz (10 msec duration,and DHB was administered twice daily (100 mg/kg body
weight each time), the first time intraperitoneally in com- 1 msec rise and fall time) were generated using a SigGen
software package (Tucker-Davis Technologies, Gainsville,bination with gentamicin and a second time intraperito-
neally 8 to 10 hours later. After the end of the gentamicin FL, USA) and presented to the left external auditory
meatus in a closed acoustic system through an ear bartreatment, twice-daily injections of DHB were continued
for one more week. Gentamicin was dissolved in physio- connected to a Beyer DT-48 transducer (Beyer Dynamic,
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Farmingdale, NY, USA). ABRs from the left ears were
obtained from the anesthetized animals in a one-channel
recording using an in-house constructed amplifier. The
active electrode was placed at the vertex, in the midline
of the scalp between the external auditory canals. The
reference electrode was placed subcutaneously below
the pinna of the right ear, and the ground electrode
was inserted contralaterally. The output was fed to an
amplifier, viewed on an oscilloscope, and recorded. The
average responses from 512 stimuli were obtained at
5 dB intervals near threshold. Threshold was defined as
the lowest stimulus level at which a positive waveform
in the evoked response trace was evident. Thresholds at
each frequency were verified at least twice, and threshold
shifts were calculated for individual animals by compari-
Fig. 1. Serum kinetics of gentamicin. Guinea pigs (from Murphy’s
son to their threshold before treatments. The final ABR Breeding Laboratories) received varying doses of gentamicin: (d) 60
mg/kg; (j) 100 mg/kg; (m) 120 mg/kg; (3) 180 mg/kg. Blood wasof each animal was taken and interpreted without knowl-
drawn from two animals at each time point on day 1. Gentamicin wasedge of the treatment history. determined by a microbiological assay as described in the Methods
section. Data are means 6 SD.
Histopathology of the cochlea
Seven weeks after the start of drug administration,
three animals randomly chosen from each group in the
study of twice-daily protection were deeply anesthetized Ototoxicity of intraperitoneal gentamicin
in a CO2 chamber and decapitated, and their auditory Significant threshold shifts developed within two
bullae were removed. The round and oval windows and weeks of intraperitoneal gentamicin treatment. For com-
the apex of the cochlea were opened. The cochlea was parison, a parallel study was conducted assessing audi-
tory deficits following subcutaneous injections of genta-perfused at 48C with 4% paraformaldehyde in 10 mmol/L
micin (Fig. 2). The time course was essentially identicalphosphate-buffered saline (PBS), pH 7.4, and kept in
with damage progressing after the end of the two-weekthis solution overnight. The cochlea was then washed
treatment and maximal threshold shifts reached by threewith cold PBS three times for 10 minutes each. Following
weeks. A frequency gradient was also evident in boththe fixation, preparations of the organ of Corti were
routes of application with the highest threshold shift ofstained with rhodamine phalloidine for 45 minutes [27],
over 60 dB found at 18 kHz. The effects of intraperito-microdissected into individual turns, and mounted on
neal and subcutaneous application were similar at 18 andglass slides (GVA Mounting Solution; Zymed Labora-
8 kHz, but animals receiving gentamicin intraperitone-tories, Inc., San Francisco, CA, USA). Hair cells were
ally sustained a significantly greater permanent hearing
counted using fluorescence microscopy. loss at 3 kHz (P , 0.05). Control animals on saline only
maintained stable thresholds (data not shown).
Statistical analysis
Protection from ototoxicityData were statistically evaluated by analysis of vari-
ance with Newman-Keuls post hoc test for significance Once-daily protection. A single daily intraperitoneal
injection of DHB and mannitol combined with gentami-(P , 0.05) using Primer of Biostatistics software (McGraw-
cin was partially effective in attenuating the gentamicin-Hill Software, New York, NY, USA).
induced threshold shift (Fig. 3). Protection was signifi-
cant at 18 kHz (P 5 0.03) but not at 3 kHz and 9 kHz
(P 5 0.1).RESULTS
A study using a-lipoic acid as a protectant againstSerum kinetics of gentamicin
ototoxicity was prematurely terminated. Intramuscular
For a pharmacokinetic study, guinea pigs received dif- injections of a-lipoic acid had been successfully tested
ferent doses of gentamicin (60, 100, 120, or 180 mg genta- as a protectant against intramuscular amikacin [23].
micin base/kg body weight). The uptake of gentamicin However, combining gentamicin with intraperitoneal in-
into serum was rapid, and serum levels essentially re- jections of 100 mg lipoic acid/kg body weight resulted
in enhanced weight loss and death of several animals.flected the injected dose (Fig. 1).
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Fig. 2. Auditory deficits after intraperitoneal
and subcutaneous injections. Guinea pigs from
Elm Hill Breeding Laboratory were treated
with 135 mg gentamicin/kg body wt daily for
14 days either by intraperitoneal (d) or subcu-
taneous (h) injection (N 5 6 per group). Ani-
mals developed significant threshold shifts at
8 and 18 kHz (P , 0.05), which did not differ
between the groups. At 3 kHz, however,
animals receiving gentamicin intraperitone-
ally showed a significantly greater permanent
threshold shift than animals treated by subcu-
taneous injection (P , 0.05).
Twice-daily protection. This study increased the daily quencies. At the end of the study (7 weeks), hearing loss
was reduced from 56 to 28 dB at 18 kHz (P , 0.01),antioxidant level and prolonged the period of protective
treatment (Fig. 4). The result was a significant reduction from 47 to 13 dB at 8 kHz (P , 0.01), and from 36 to
10 dB at 3 kHz (P , 0.01).of gentamicin-induced threshold shifts at all tested fre-
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Fig. 3. Effect of once-daily protective treat-
ment on hearing loss. Guinea pigs from Mur-
phy’s Breeding Laboratories were treated with
120 mg gentamicin (Gm)/kg body wt daily for
19 days (N 5 10) or with gentamicin combined
with DHB/mannitol (N 5 5), as described in
the Methods section. Thresholds were deter-
mined by ABR at 4.5 week. Numbers are
means 6 SD. *Gentamicin alone (N 5 10)
does not differ from gentamicin plus pro-
tectants (N 5 5, P 5 0.1). **Gentamicin alone
significantly differs from gentamicin plus pro-
tectants, P , 0.05.
Animals treated with gentamicin only exhibited severe
to almost complete loss of outer hair cells in all three
rows of cells in the basal turn of the cochlea, with lesser
damage extending into the middle and some damage
into the apical turns (Fig. 6). This pattern of damage
corresponds well to the more severe threshold shift at
high frequencies (18 kHz) and the lesser effect of genta-
micin on the physiological response at low frequencies
(3 kHz). Coadministration of DHB with gentamicin sig-
nificantly reduced damage to outer hair cells in all rows.
Inner hair cells did not sustain significant damage with
gentamicin treatment.
Renal function and serum levels of gentamicin
Blood samples from animals in the study of twice-Fig. 4. Effect of twice-daily protective treatment on hearing loss.
Guinea pigs from Elm Hill Breeding Laboratory were treated with daily protection (Figs. 4 to 6) were analyzed on day 14
135 mg gentamicin (Gm)/kg body weight daily for 14 days (N 5 6) or for BUN, serum albumin, creatinine, and gentamicinwith gentamicin combined with twice-daily DHB (N 5 6). Injections
levels. Drug treatment showed a marginally significantof DHB were then continued for an additional week as described in
the Methods section. Values are means 6 SD of threshold shifts at tendency to increase BUN (0.1 . P . 0.05; Table 1).
seven weeks. * The threshold shifts in the presence of DHB were signifi- There were no other significant changes in renal parame-cantly lower at all frequencies (P , 0.05).
ters, but all values from animals receiving gentamicin
plus DHB were closer to controls than were the corre-
sponding data from animals treated with gentamicin
only.Cochlear pathology
Increased BUN correlated somewhat with serum gen-Cochlear pathology in the study on twice-daily protec-
tamicin levels (R2 5 0.46, gentamicin group, and R2 5tion was consistent with the functional deficits deter-
0.65, gentamicin plus DHB). However, gentamicin levelsmined by the ABR measurements. Surface preparations
overlapped between the groups (119 to 350 mg/mL, gen-of the organ of Corti stained with rhodamine-phalloidine
tamicin only; 112 to 260 mg/mL, gentamicin plus DHB),show the clear outline of three rows of outer and one
and there was no significant difference in the mean values.row of inner hair cells (Fig. 5A). After treatment with
There was also no correlation between individual se-gentamicin, outer hair cells disappeared, and supporting
rum levels and resulting ototoxicity in the two treatmentcells expanded into the space (Fig. 5B). Cotreatment
with DHB largely protected the hair cells (Fig. 5C). groups. At 18 kHz, five out of six animals receiving DHB
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Fig. 6. Cytocochleograms. Cytocochleograms were obtained from the
surface preparations (Fig. 5) as described in the Methods section. The
percentage of missing hair cells is plotted for the entire length of the
cochlea. OHC1 (solid line), OHC2 (dotted line), and OHC3 (dashed
line) denote cochlear outer hair cells of rows 1, 2, and 3, respectively.
Each panel represents data from an individual animal. Left panels,
gentamicin only; right panels, gentamicin combined with DHB.
Table 1. Renal functional parameters and serum gentamicin levels
BUN Creatinine
Albumin Gentamicin
Treatment g/dL lg/mL Nmg/dL
Control 2063 0.5360.08 2.260.1 — 6Fig. 5. Surface preparations. The organ of Corti of guinea pigs in the
Gentamicin 32614a 0.5860.23 2.761.0 243696 6study of “twice-daily protection” was prepared and stained as described
Gentamicinin the Methods section. Sections shown are from the basal turn of the
plus DHB 26612 0.5060.13 2.160.3 191661 6cochlea where damage by gentamicin is heaviest. (A) The rhodamine-
phalloidin stain for actin shows the orderly outline of outer hair cells Blood was sampled from animals in the study of “twice-daily protection”
(arrow heads) and the stereocilia (sensory hairs; arrows) in control (Figs. 4–6) on day 14 of treatment and analyzed as described in the Methods
animals. OHC1, OHC2, and OHC3 denote cochlear outer hair cells of section. Data are means 6 SD for samples from 6 animals per group.
a Different from controls, 0.1 . P . 0.05rows 1, 2, and 3, respectively. (B) Treatment with gentamicin eliminated
outer hair cells, evident by the disappearance of the orderly structural
arrangement and the staining for stereocilia. Their place is occupied
by expansion of supporting cells. (C) Cotreatment with DHB protects
hair cells. DISCUSSION
Two salient points arise from this study. First, gentami-
cin has similar ototoxic potential whether given intraperi-
toneally or subcutaneously. Second, protection from oto-coadministration had lower threshold shifts than the least
toxicity caused by intraperitoneal injection of gentamicinaffected animal in the gentamicin-only group despite the
can be achieved. This protection agrees with and extendsoverlap of serum gentamicin values. Even the animals
earlier observations that DHB attenuates cochlear andwith the highest gentamicin levels in the “protected”
vestibular toxicity of subcutaneously applied aminogly-gentamicin plus DHB group (241 and 260 mg/mL) had
cosides [20, 21].lower threshold shifts (29 and 30 dB at 18 kHz) than the
The first conclusion becomes evident by comparinganimals with the lowest gentamicin levels in the gentami-
the time course and pattern of hearing damage presentedcin-only group (119 and 151 mg/mL; 44 and 63 dB). At
here to the well-documented pathology following sys-3 kHz, all threshold shifts in the DHB group were lower
than in the gentamicin-only group. temic application of the drug [28]. Hearing loss usually
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develops in the course of chronic aminoglycoside admin- is thus not based on an indirect effect through decreasing
drug serum levels, but is consistent with the hypothesisistration requiring days to weeks to reach its maximal
threshold shift. High frequencies, represented in the basal that gentamicin exerts its toxicity via the formation of an
iron complex catalyzing superoxide production [16, 18].coils of the cochlea, are affected more than the low fre-
quencies represented in the apical coils of the cochlea. DHB, as an iron chelator and antioxidant, would lower
available free iron, reducing the formation of the redoxThe morphological basis of the hearing loss is primarily
a destruction of outer hair cells in the organ of Corti. active iron-gentamicin complex and possibly also sup-
pressing subsequent Fenton reactions [29]. It remains toIt is not surprising that intraperitoneal application of
gentamicin causes a pathology comparable to other sys- be established whether these interactions occur locally
in the cochlea or in other compartments. It is also unre-temic applications. Gentamicin uptake into serum is
rapid from the peritoneum, and the resulting serum lev- solved whether antioxidants could attenuate hearing loss
in cases of hypersensitivity to aminoglycosides based on aels appear even higher than after similar doses injected
subcutaneously [24, 29]. Consistent with this observation, mutation in location 1555 of the mitochondrial ribosomal
RNA [36]. In patients carrying this mutation, a singleboth the functional deficit at 3 kHz and the correspond-
ing hair cell loss near the apex are significantly greater injection may cause profound hearing loss, although the
mutation does not enhance vestibular sensitivity to amino-following intraperitoneal injection.
The similar pattern of ototoxicity after subcutaneous glycosides. Little is known about the underlying mecha-
nisms, and it is impossible to predict the efficacy of anyand intraperitoneal injections in the guinea pig agrees
well with clinical observations. In humans, gentamicin prophylactic treatment.
While a single daily administration of DHB providedprimarily affects vestibular function, and the intraperito-
neal route is not safer than intravenous or intramuscular limited protection, a twice-daily DHB regimen was highly
effective at all tested frequencies. The reduction of aadministration [30]. However, treatment with DHB also
protects from the vestibular side effects of aminoglyco- 60 dB threshold shift (at 18 kHz) to less than 30 dB
corresponds to a reduction from a “severe” to a “moder-sides, as shown for gentamicin [20] and streptomycin [21]
in guinea pigs. While ototoxicity may develop regardless ate” hearing loss. It also speaks to the efficacy of the
treatment that protection is achieved at drug concentra-of the route of administration, the actual incidence of
loss of hearing or balance in patients will depend on a tions (135 mg/kg body weight 3 14 days) far exceeding
the human clinical usage. Moreover, DHB and othernumber of additional parameters. Generally, the amount
of drug and the duration of treatment are determining antioxidants do not interfere with the antibacterial activ-
ity or the serum levels of aminoglycosides [20, 21, 28],factors. Metabolic stress resulting from infections or mal-
nutrition may predispose toward the adverse effects of critical points in considering a clinical application.
2,3-Dihydroxybenzoate was initially intended as anaminoglycosides [31]. Nutritional supplements may there-
fore be indicated to reduce the risk of ototoxicity, but aspirin analogue [37] and later as an iron-chelating agent
[38]. It was tested clinically in patients suffering fromthe addition of iron would be detrimental. Iron supple-
mentation in experimental animals enhances both amino- thalassemia major. At a dose of 100 mg/kg/day for one
year, no significant side effects were apparent, and pa-glycoside nephrotoxicity and ototoxicity [32–34].
Aminoglycoside antibiotics have both ototoxic and tient tolerance to this drug was good [26]. Likewise, DHB
had negligible or no toxicity in experimental animalsnephrotoxic potential. However, nephrotoxicity and oto-
toxicity are not necessarily expressed together in experi- [38, 39], and only very high doses (500 mg/kg) were
associated with renal toxicity in rats [40]. We tested upmental animals or in patients [35]. In guinea pigs, the
ototoxic effects of gentamicin are far more pronounced to 300 mg DHB/kg in guinea pigs and saw no detrimental
effects on hearing thresholds or histopathology [21].than the nephrotoxic side effects. It is important to con-
sider that impaired renal function may lead to higher drug Moderate doses (100 mg/kg) even reduced gentamicin-
induced damage to the kidney [25], suggesting that theserum levels, potentially resulting in increased ototoxi-
city. A therapeutic intervention might reduce ototoxicity mechanisms of ototoxicity and nephrotoxicity are simi-
lar. Consequently, DHB appears to have an almost idealunder such circumstances by restoring renal function and
lowering drug serum levels. In our study, parameters of potential as a protective agent in patients receiving
aminoglycosides. However, it is currently not a clinicallyrenal function are only slightly elevated, and therefore,
it is difficult to evaluate any beneficial effects of DHB approved drug.
In summary, the principle of antioxidant therapy, de-cotreatment on the kidney. However, DHB may attenu-
ate aminoglycoside-induced nephrotoxicity in the rat [25]. veloped from systemically injected gentamicin, is also
applicable to intraperitoneally administered gentamicin.Most significant for an interpretation of the action of
DHB on ototoxicity is the fact that serum gentamicin Other recently confirmed antioxidant antidotes to amino-
glycoside ototoxicity include salicylate [29] and D-methio-levels in the two treatment groups did not correlate with
the resulting ototoxicity. The protective action of DHB nine [41]. Since antioxidant therapy is a well-established
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